Blockage of Glyoxalase I Inhibits Colorectal Tumorigenesis and Tumor Growth via Upregulation of STAT1, p53, and Bax and Downregulation of c-Myc and Bcl-2

GlyoxalaseI (GLOI) is an enzyme that catalyzes methylglyoxal metabolism. Overexpression of GLOI has been documented in numerous tumor tissues, including colorectal cancer (CRC). The antitumor effects of GLOI depletion have been demonstrated in some types of cancer, but its role in CRC and the mechanisms underlying this activity remain largely unknown. Our purpose was to investigate the antitumor effects of depleted GLOI on CRC in vitro and in vivo. RNA interference was used to deplete GLOI activity in four CRC cell lines. The cells’ proliferation, apoptosis, migration, and invasion were assessed by using the Cell Counting Kit-8, plate colony formation assay, flow cytometry, and transwell assays. Protein and mRNA levels were analyzed by western blot and quantitative real-time PCR (qRT-PCR), respectively. The antitumor effect of GLOI depletion in vivo was investigated in a SW620 xenograft tumor model in BALB/c nude mice. Our results show that GLOI is over-expressed in the CRC cell lines. GLOI depletion inhibited the proliferation, colony formation, migration, and invasion and induced apoptosis of all CRC cells compared with the controls. The levels of signal transducer and activator of transcription 1 (STAT1), p53, and Bcl-2 assaciated X protein (Bax) were upregulated by GLOI depletion, while cellular homologue of avian myelocytomatosis virus oncogene (c-Myc) and B cell lymphoma/lewkmia-2 (Bcl-2) were downregulated. Moreover, the growth of SW620-induced CRC tumors in BALB/c nude mice was significantly attenuated by GLOI depletion. The expression levels of STAT1, p53, and Bax were increased and those of c-Myc and Bcl-2 were decreased in the GLOI-depleted tumors. Our findings demonstrate that GLOI depletion has an antitumor effect through the STAT1 or p53 signaling pathways in CRC, suggesting that GLOI is a potential therapeutic target.

[1]  M. Huycke,et al.  Microbiome‐driven carcinogenesis in colorectal cancer: Models and mechanisms , 2017, Free radical biology & medicine.

[2]  P. Delvenne,et al.  Methylglyoxal-Mediated Stress Correlates with High Metabolic Activity and Promotes Tumor Growth in Colorectal Cancer , 2017, International journal of molecular sciences.

[3]  Xiaolong Liu,et al.  Targeting STAT1 in Both Cancer and Insulin Resistance Diseases. , 2016, Current protein & peptide science.

[4]  Zuohua Liu,et al.  Expression Pattern and Regulatory Role of microRNA-23a in Conjugated Linoleic Acids-Induced Apoptosis of Adipocytes , 2016, Cellular Physiology and Biochemistry.

[5]  Paul J Thornalley,et al.  Glyoxalase 1-knockdown in human aortic endothelial cells – effect on the proteome and endothelial function estimates , 2016, Scientific Reports.

[6]  Cheng Huang,et al.  MicroRNA-208a Potentiates Angiotensin II-triggered Cardiac Myoblasts Apoptosis via Inhibiting Nemo-like Kinase (NLK). , 2016, Current pharmaceutical design.

[7]  T. He,et al.  Methylglyoxal suppresses human colon cancer cell lines and tumor growth in a mouse model by impairing glycolytic metabolism of cancer cells associated with down-regulation of c-Myc expression , 2016, Cancer biology & therapy.

[8]  Haisheng Peng,et al.  A new peptide ligand for colon cancer targeted delivery of micelles , 2016, Drug delivery.

[9]  P. Hwu,et al.  Defective STAT1 activation associated with impaired IFN-γ production in NK and T lymphocytes from metastatic melanoma patients treated with IL-2 , 2016, Oncotarget.

[10]  T. He,et al.  Metformin inhibits prostate cancer cell proliferation, migration, and tumor growth through upregulation of PEDF expression , 2016, Cancer biology & therapy.

[11]  A. Koromilas,et al.  STAT1-mediated translational control in tumor suppression and antitumor therapies , 2016, Molecular & cellular oncology.

[12]  P. Korkolopoulou,et al.  Clinical significance of AGE-RAGE axis in colorectal cancer: associations with glyoxalase-I, adiponectin receptor expression and prognosis , 2016, BMC Cancer.

[13]  Q. Meng,et al.  Effects of methylglyoxal and glyoxalase I inhibition on breast cancer cells proliferation, invasion, and apoptosis through modulation of MAPKs, MMP9, and Bcl-2 , 2016, Cancer biology & therapy.

[14]  M. Barton.  Earlier adjuvant therapy is beneficial in patients with breast and colon cancer , 2016, CA: a cancer journal for clinicians.

[15]  A. Jemal,et al.  Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[16]  J. Wang,et al.  STAT1 inhibits human hepatocellular carcinoma cell growth through induction of p53 and Fbxw7 , 2015, Cancer Cell International.

[17]  Amit Kumar Srivastava,et al.  XPC inhibits NSCLC cell proliferation and migration by enhancing E-Cadherin expression , 2015, Oncotarget.

[18]  D. Ding,et al.  Glyoxalase I is differentially expressed in cutaneous neoplasms and contributes to the progression of squamous cell carcinoma. , 2015, The Journal of investigative dermatology.

[19]  Cunshuan Xu,et al.  Glyoxalase I in Tumor Cell Proliferation and Survival and as a Potential Target for Anticancer Therapy , 2014, Oncology Research and Treatment.

[20]  B. Baron,et al.  Proteomic analysis indicates that overexpression and nuclear translocation of lactoylglutathione lyase (GLO1) is associated with tumor progression in murine fibrosarcoma , 2014, Electrophoresis.

[21]  S. Gill.  Adjuvant therapy for resected high-risk colon cancer: Current standards and controversies , 2014, Indian Journal of Medical and Paediatric Oncology.

[22]  I. Palumbo,et al.  Glyoxalase I inhibition induces apoptosis in irradiated MCF-7 cells via a novel mechanism involving Hsp27, p53 and NF-κB , 2014, British Journal of Cancer.

[23]  Q. Meng,et al.  Down-Regulation of mir-221 and mir-222 Restrain Prostate Cancer Cell Proliferation and Migration That Is Partly Mediated by Activation of SIRT1 , 2014, PloS one.

[24]  F. Hosoda,et al.  Integrated genomic and functional analyses reveal glyoxalase I as a novel metabolic oncogene in human gastric cancer , 2014, Oncogene.

[25]  Qi Chen,et al.  Glyoxalase 1 is up-regulated in hepatocellular carcinoma and is essential for HCC cell proliferation , 2013, Biotechnology Letters.

[26]  A. Koromilas,et al.  The tumor suppressor function of STAT1 in breast cancer , 2013, JAK-STAT.

[27]  K. Fettucciari,et al.  Role of glyoxalase I in the proliferation and apoptosis control of human LNCaP and PC3 prostate cancer cells , 2013, The Prostate.

[28]  Margaret G. Distler,et al.  Role of Glyoxalase 1 (Glo1) and methylglyoxal (MG) in behavior: recent advances and mechanistic insights , 2012, Front. Gene..

[29]  Ying Liang,et al.  Correction: Glyoxalase-I Is a Novel Prognosis Factor Associated with Gastric Cancer Progression , 2012, PLoS ONE.

[30]  N. Iizuka,et al.  Glyoxalase I (GLO1) is up-regulated in pancreatic cancerous tissues compared with related non-cancerous tissues. , 2012, Anticancer research.

[31]  Tatsushi Yoshida,et al.  Targeting the Glyoxalase Pathway Enhances TRAIL Efficacy in Cancer Cells by Downregulating the Expression of Antiapoptotic Molecules , 2012, Molecular Cancer Therapeutics.

[32]  Ying Liang,et al.  Glyoxalase-I Is a Novel Prognosis Factor Associated with Gastric Cancer Progression , 2012, PloS one.

[33]  Paul J Thornalley,et al.  Glyoxalase in tumourigenesis and multidrug resistance. , 2011, Seminars in cell & developmental biology.

[34]  J. Arias,et al.  Drug targeting strategies in cancer treatment: an overview. , 2011, Mini reviews in medicinal chemistry.

[35]  M. Stratton,et al.  Imidazopurinones are markers of physiological genomic damage linked to DNA instability and glyoxalase 1-associated tumour multidrug resistance , 2010, Nucleic acids research.

[36]  K. Uchida,et al.  GLO1 overexpression in human malignant melanoma , 2010, Melanoma research.

[37]  Hai-Bin Luo,et al.  Binding of curcumin with glyoxalase I: Molecular docking, molecular dynamics simulations, and kinetics analysis. , 2010, Biophysical chemistry.

[38]  F. Baran-Marszak,et al.  Efficient killing of SW480 colon carcinoma cells by a signal transducer and activator of transcription (STAT) 3 hairpin decoy oligodeoxynucleotide – interference with interferon‐γ‐STAT1‐mediated killing , 2009, The FEBS journal.

[39]  Myung-Shik Lee,et al.  STAT1 as a key modulator of cell death. , 2007, Cellular signalling.

[40]  V. Talesa,et al.  Overexpression of Glyoxalase System Enzymes in Human Kidney Tumor , 2006, Cancer journal.

[41]  K. Nilsson,et al.  Ser727/Tyr701-phosphorylated Stat1 is required for the regulation of c-Myc, cyclins, and p27Kip1 associated with ATRA-induced G0/G1 arrest of U-937 cells. , 2003, Blood.

[42]  T. Tsuruo,et al.  Selective activation of apoptosis program by S-p-bromobenzylglutathione cyclopentyl diester in glyoxalase I-overexpressing human lung cancer cells. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[43]  T. Tsuruo,et al.  Glyoxalase I is involved in resistance of human leukemia cells to antitumor agent-induced apoptosis. , 2000, Blood.

[44]  H. Tazaki,et al.  Glyoxalase I activity in human prostate cancer: a potential marker and importance in chemotherapy. , 1999, The Journal of urology.

[45]  A. Godwin,et al.  Cloning and characterization of human colon glyoxalase-I. , 1993, The Journal of biological chemistry.

[46]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.